However, fasting and glucagon-stimulated C-peptide levels did not predict responsiveness to metformin [25], nor did random C-peptide testing predict responsiveness to combination of metformin and a sulfonylurea [26] when added to insulin-treated patients with type 2 diabetes. This evidence concerns the gene INS and type 2 diabetes mellitus.